State v. Boyer ( 2023 )


Menu:
  •                IN THE COURT OF APPEALS OF THE STATE OF IDAHO
    Docket No. 49660
    STATE OF IDAHO,                               )
    )        Filed: July 20, 2023
    Plaintiff-Respondent,                  )
    )        Melanie Gagnepain, Clerk
    v.                                            )
    )        THIS IS AN UNPUBLISHED
    MELODY DEVONNA BOYER,                         )        OPINION AND SHALL NOT
    )        BE CITED AS AUTHORITY
    Defendant-Appellant.                   )
    )
    Appeal from the District Court of the Fourth Judicial District, State of Idaho, Ada
    County. Hon. Jason D. Scott, District Judge.
    Judgment of conviction for possession of a controlled substance, affirmed.
    Eric D. Fredericksen, State Appellate Public Defender; Kimberly A. Coster, Deputy
    Appellate Public Defender, Boise, for appellant.
    Hon. Raúl R. Labrador, Attorney General; Andrew V. Wake, Deputy Attorney
    General, Boise, for respondent.
    ________________________________________________
    HUSKEY, Judge
    Melody Devonna Boyer appeals from the judgment of conviction finding her guilty of
    trafficking in heroin, possession of a controlled substance (Suboxone), and possession of drug
    paraphernalia. Boyer argues the district court erred in admitting evidence of the unopened, intact
    box with a package label of “Suboxone” and a list of the ingredients pursuant to Idaho Rule of
    Evidence 803(17) exception to the prohibition against hearsay. The State argues the district court
    did not err in admitting the evidence but even if it did, the error was harmless. This Court holds
    that any error in admitting the evidence was harmless and the judgment of conviction is affirmed.
    I.
    FACTUAL AND PROCEDURAL BACKGROUND
    Boyer was driving her boyfriend’s pickup truck. Law enforcement performed a traffic stop
    after Boyer drove past a construction roadblock. Thereafter, the officers searched a bag belonging
    1
    to Boyer and found an unopened, intact box labeled “Suboxone,” which listed the ingredients of
    Suboxone as “buprenorphine and naloxone.” Officers also located a golf-ball-size amount of
    heroin in a duffle bag that Boyer claimed belonged to her boyfriend.
    The State charged Boyer with felony trafficking in heroin, 
    Idaho Code § 37
    -
    2732B(a)(6)(B), misdemeanor unlawful possession of a controlled substance, Suboxone, I.C. § 37-
    2732(c), and misdemeanor possession of drug paraphernalia, I.C. § 37-2734A. Following a jury
    trial, Boyer was convicted of all three counts; she does not appeal either her conviction for
    trafficking in heroin or her conviction for possessing paraphernalia. For misdemeanor possession
    of a controlled substance, Boyer was sentenced to 256 days in jail, with 256 days credit for time
    served. Boyer appeals.
    II.
    STANDARD OF REVIEW
    Error is not reversible unless it is prejudicial. State v. Stell, 
    162 Idaho 827
    , 830, 
    405 P.3d 612
    , 615 (Ct. App. 2017).           Where a criminal defendant shows an error based on a
    contemporaneously objected-to, nonconstitutional violation, the State then has the burden of
    demonstrating to the appellate court beyond a reasonable doubt the error did not contribute to the
    jury’s verdict. State v. Montgomery, 
    163 Idaho 40
    , 46, 
    408 P.3d 38
    , 44 (2017). Thus, we examine
    whether the alleged error complained of in the present case was harmless. See 
    id.
     Harmless error
    is error unimportant in relation to everything else the jury considered on the issue in question, as
    revealed in the record. State v. Garcia, 
    166 Idaho 661
    , 674, 
    462 P.3d 1125
    , 1138 (2020). This
    standard “requires weighing the probative force of the record as a whole while excluding the
    erroneous evidence and at the same time comparing it against the probative force of the error.” 
    Id.
    If the error’s effect is minimal compared to the probative force of the record establishing guilt
    beyond a reasonable doubt without the error, then the error did not contribute to the verdict
    rendered and is harmless. 
    Id.
     The reviewing court must take into account what effect the error
    had, or reasonably may have had, on the jury in the context of the total setting and in relation to
    all else that happened, which necessarily includes the evidence presented. Kotteakos v. United
    States, 
    328 U.S. 750
    , 764 (1946).
    2
    III.
    ANALYSIS
    Boyer argues on appeal the district court erred in finding that the packaging containing the
    word “Suboxone” and the list of ingredients was admissible pursuant to I.R.E. 803(17) because
    the packaging label was hearsay evidence regarding the contents of the box. The district court
    agreed that the package label was likely hearsay, but nevertheless ruled that the evidence was
    admissible under the “market reports” exception set out in I.R.E. 803(17). The State argues that
    the district court did not err; the label, as well as the list of ingredients, individually, met the
    requirements of I.R.E. 803(17) but even if the district court erred in admitting the evidence, any
    error was harmless in light of Boyer’s trial testimony that the Suboxone in the box was hers and
    she had a prescription for it.
    Boyer argues that I.R.E. 803(17) does not apply to a name on a box because a name is not
    a market quotation, list, directory, or compilation, as required by the rule. Alternatively, Boyer
    argues that to the extent Suboxone’s ingredients, buprenorphine and naloxone, are listed on the
    package, the “list” would establish that Suboxone is comprised of those two compounds but would
    not qualify as substantive proof that the box contained those two compounds. Finally, Boyer
    argues that in order for I.R.E. 803(17) to apply, the proponent must show “necessity and reliability”
    pursuant to United States v. Woods, 
    321 F.3d 361
    , 363 (3d Cir. 2003), neither of which was
    established by the State.
    In contrast, the State argues the district court correctly concluded that where “drug
    packaging that is intact and unopened [includes] a list of ingredients in the package,” that list is a
    “market list within the meaning of Rule 803(17).” Second, the State argues that Boyer failed to
    preserve a claim that the list of Suboxone’s ingredients was irrelevant. To the extent “reliability”
    and “necessity” are required as predicate facts for admission, the State argues the district court
    correctly found that pharmaceutical labels are heavily regulated and broadly relied upon within the
    medical community and, therefore, have sufficient circumstantial guarantees of trustworthiness.
    Third, the State contends that Boyer’s definition of necessity is not supported by the language of
    I.R.E. 803(17) and reading the rule as Boyer does would lead to absurd results. Finally, the State
    argues that any error in admitting the evidence was harmless because Boyer testified that she had
    a prescription for the Suboxone that was found and although she did not know how many Suboxone
    strips the package contained, she did not disagree that the number was twelve. Consequently, it
    3
    was Boyer’s testimony, not the package label, that established the substance was Suboxone and
    that it was hers.
    We need not address the evidentiary issue because any error in admitting the label with the
    word “Suboxone,” and the list of ingredients was harmless in light of Boyer’s theory of defense
    and her testimony. Defense counsel told the jury in its opening statement that Boyer was “charged
    with possession of Suboxone, and the evidence will show that she had a prescription for that
    Suboxone.” (Emphasis added.) The Suboxone referenced by defense counsel was the Suboxone
    found in Boyer’s bag. On cross-examination of one of the officers, Boyer clarified that the
    Suboxone box was found in a flower-print bag, which Boyer later confirmed was hers. When
    cross-examining the officer who located the Suboxone about whether the officer also located a
    prescription for Suboxone, the district court asked defense counsel, “I gather when the defendant
    testifies, she’s ultimately going to say she has a Suboxone prescription[?]” Defense counsel
    answered, “Yes.” Thereafter, Boyer objected to State’s Exhibit 9, a photograph of the Suboxone
    box. The district court discussed the objection and whether a limiting instruction would be
    appropriate. The district court also noted that the State had evidence Boyer admitted she possessed
    Suboxone and claimed to have a prescription for it. The State indicated that if the district court
    was inclined to provide a limiting instruction regarding the Suboxone, it would re-call an officer
    who would testify that Boyer “told [the officer] that that was her Suboxone” and she “had a
    prescription for it.” The district court admitted Exhibit 9 pursuant to I.R.E. 803(17).
    During Boyer’s direct examination, counsel attempted to introduce two prescriptions for
    Suboxone. The first was an Idaho prescription dated August 2017 that did not include refills and
    was no longer valid. The second was a California prescription dated 2020, which had been filled
    on July 17, 2020, and also did not include refills. The State objected to the admission of both
    exhibits as irrelevant, and the district court sustained the objection. During her cross-examination,
    Boyer acknowledged she had previously testified that she had a prescription for the Suboxone that
    was found in the vehicle, did not disagree that the number of Suboxone strips recovered was twelve,
    and that she asked her boyfriend to print a picture of a Suboxone prescription that was on her
    phone, “preferably without the dates.” Thus, Boyer’s testimony established that she knowingly
    possessed the Suboxone that was found in the vehicle, but she believed the possession was lawful
    because she had a prescription.
    4
    Despite her trial testimony, Boyer argues on appeal that absent the Suboxone package
    label, the State failed to prove beyond a reasonable doubt that the substance in the unopened, intact
    package was Suboxone because the contents of the Suboxone package were not confirmed by
    chemical testing and that counterfeit substances exist. Given this lack of proof, Boyer argues that
    the admission of Exhibit 9 for purposes of establishing that the substance found was Suboxone is
    not harmless. This Court disagrees. Regardless of whether the contents of the Suboxone package
    were tested, Boyer’s testimony that she knew the substance she possessed was Suboxone was
    sufficient for the jury to find beyond a reasonable doubt that Boyer possessed Suboxone and any
    evidence confirming the identity of the substance as Suboxone was merely cumulative of Boyer’s
    testimony.
    When weighing the probative force of the record as a whole while excluding the alleged
    erroneous evidence and at the same time comparing it against the probative force of the error, any
    error in admitting the packaging label was minimal because even absent the admission of the
    exhibit with the label, there was sufficient evidence to sustain the conviction. Boyer’s theory of
    defense was that her possession of Suboxone was lawful, she testified she knowingly possessed
    Suboxone, and the fact that she failed to present evidence rendering her possession lawful does
    not negate her other admissions. In light of Boyer’s testimony, the probative force of the record
    establishes her guilt beyond a reasonable doubt without the admission of the Suboxone label and,
    thus, any error admitting the label did not contribute to the verdict rendered and is harmless.
    IV.
    CONCLUSION
    Any error in admitting the evidence of the Suboxone packaging was harmless, and Boyer’s
    judgment of conviction for misdemeanor possession of a controlled substance is affirmed.
    Chief Judge LORELLO and Judge GRATTON CONCUR.
    5
    

Document Info

Docket Number: 49660

Filed Date: 7/20/2023

Precedential Status: Non-Precedential

Modified Date: 7/20/2023